Author, as appears in the article.: Rosado-Sanchez, Isaac; Rodriguez-Gallego, Esther; Peraire, Joaquim; Vilades, Consuelo; Herrero, Pol; Fanjul, Fran; Gutierrez, Felix; Bernal, Enrique; Pelazas, Ricardo; Leal, Manuel; Veloso, Sergi; Lopez-Dupla, Miguel; Blanco, Julia; Vidal, Francesc; Maria Pacheco, Yolanda; Rull, Anna
Department: Medicina i Cirurgia
URV's Author/s: HERRERO GIL, POL / López Dupla, Jesús Miguel / Peraire Forner, José Joaquin / Rodríguez Gallego, Esther / RULL AIXA, ANNA / SIRVENT CALVERA, JUAN JOSÉ / Veloso Esteban, Sergio / Vidal Marsal, Francisco / Vilades Laborda, Consuelo Gloria
Keywords: Risk Poor immune recovery Pipecolic acid Nmr-based lipoprotein profile Ms-based metabolomics Mortality Middle aged Metabolomics Mass spectrometry Male Magnetic resonance spectroscopy Macrophages Lymphocytes Low cd4 counts Lipoproteins Inflammation Humans Hiv-1 Hiv infections Hiv Glutamine Follow-up studies Differentiation Cohort studies Cd4+ t-cell turnover Cart Biomarkers Antiretroviral therapy Anti-hiv agents Adult Activation
Abstract: The immunological, biochemical and molecular mechanisms associated with poor immune recovery are far from known, and metabolomic profiling offers additional value to traditional soluble markers. Here, we present novel and relevant data that could contribute to better understanding of the molecular mechanisms preceding a discordant response and HIV progression under suppressive combined antiretroviral therapy (cART). Integrated data from nuclear magnetic resonance (NMR)-based lipoprotein profiles, mass spectrometry (MS)-based metabolomics and soluble plasma biomarkers help to build prognostic and immunological progression tools that enable the differentiation of HIV-infected subjects based on their immune recovery status after 96 weeks of suppressive cART. The metabolomic signature of ART-naïve HIV subjects with a subsequent late immune recovery is the expression of pro-inflammatory molecules and glutaminolysis, which is likely related to elevate T-cell turnover in these patients. The knowledge about how these metabolic pathways are interconnected and regulated provides new targets for future therapeutic interventions not only in HIV infection but also in other metabolic disorders such as human cancers where glutaminolysis is the alternative pathway for energy production in tumor cells to meet their requirement of rapid proliferation.© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.
Thematic Areas: Saúde coletiva Química Psicología Odontología Nutrição Medicine, research & experimental Medicine (miscellaneous) Medicine (all) Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 01435221
Author's mail: sergio.veloso@urv.cat joaquim.peraire@urv.cat consuelo.vilades@urv.cat esther.rodriguez@urv.cat francesc.vidal@urv.cat jesusmiguel.lopez@urv.cat
Author identifier: 0000-0001-7808-5479 0000-0002-2991-9593 0000-0002-6692-6186 0000-0002-9141-2523
Record's date: 2025-02-19
Paper version: info:eu-repo/semantics/acceptedVersion
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Paper original source: Clinical Science. 133 (8): 997-1010
APA: Rosado-Sanchez, Isaac; Rodriguez-Gallego, Esther; Peraire, Joaquim; Vilades, Consuelo; Herrero, Pol; Fanjul, Fran; Gutierrez, Felix; Bernal, Enrique; (2019). Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients. Clinical Science, 133(8), 997-1010. DOI: 10.1042/CS20190111
Entity: Universitat Rovira i Virgili
Journal publication year: 2019
Publication Type: Journal Publications
Repositori URV